Search clinical trials for: PBF-509_160 mg

Total 12231 results

Palobiofarma SL
Novartis; H. Lee Moffitt Cancer Center and Research Institute

Completed

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)

Non-small Cell Lung Cancer (NSCLC)

United States
Palobiofarma SL
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Terminated

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers

Huntington Disease

Spain
Fundació Institut de Recerca de l'Hospital de la...
Palo Biofarma, S.L

Completed

Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics

Asthma

Spain
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Bioprojet

Completed

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Parkinson's Disease | Excessive Daytime Sleepiness

France
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

SARS-CoV-2 Infection, COVID-19

United States
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Medibiofarma S.L.

Completed

Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

Safety and Pharmacokinetic

Spain
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
9 Meters Biopharma, Inc.

Terminated

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

Short Bowel Syndrome

United States
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Pfizer

Completed

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Healthy

United States
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Pfizer

Completed

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Healthy

Netherlands
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
GlaxoSmithKline

Completed

Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)

Dermatitis

United Kingdom
Pfizer

Completed

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden
Pfizer

Completed

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Systemic Lupus Erythematosus

Spain, United States, Taiwan, Belgium, Czechia, Japan, Hungary, Germany, United Kingdom, China, France, Australia, Bulgaria, Hong Kong, Korea, Republic of, Colombia, Argentina, Canada, Greece, Italy, Mexico, Poland, Portugal, Romania, S... and more
Supernus Pharmaceuticals, Inc.

Withdrawn

Classroom Study of SPN-812 in Children With ADHD

ADHD
Pfizer

Terminated

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

Type 2 Diabetes Mellitus (T2DM)

United States
Pfizer

Withdrawn

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

Dementia | Alzheimer's Disease | Dimebon | Investigational Drug
Pfizer

Completed

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Canada, United States, Korea, Republic of, Puerto Rico
Pfizer

Completed

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada
Palobiofarma SL
Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology...

Completed

Study of PBF-999 in Solid Tumour Advanced Cancer

Cancer

Spain
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects

Healthy

Singapore
Institute of Tropical Medicine, Belgium
World Bank; Ministry of Health, Burundi; Institut de Statistiques, Burundi (ISTEEBU) and other collaborators

Completed

Measuring and Understanding the Effects of a Performance Based Financing Scheme Applied to Nutrition Services in Burundi (NutriPBF)

Malnutrition

3

Subscribe